Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis

Viral Immunol. 2020 Jun;33(5):404-412. doi: 10.1089/vim.2019.0156. Epub 2020 Apr 21.

Abstract

Human papilloma virus has a clearly demonstrated role in cervical and head and neck cancers, but viral etiology for other solid tumors is less well understood. To expand this area of research, we obtained and analyzed the immune receptor recombinations available from both blood and tumor samples, through mining of exome files produced from those sources, for 32 cancer types represented by the cancer genome atlas (TCGA). Among TCGA data sets, the recovery frequency for antiviral complementarity determining region-3 sequences (CDR3s), for T cell receptor-alpha and T cell receptor-beta, ranged from 0% to 21% of the patients, for the different cancer types, with breast, lung, pancreatic, and thymus cancers representing the highest of that range, particularly for tumor tissue resident T cells. In several cases, recovery of the antiviral CDR3s associated with distinct survival rates, and in all of these cases, the recovery of an antiviral CDR3 associated with a worse survival rate.

Keywords: TCGA; antiviral CDR3s; cancer; exome files; immune cell infiltrates; survival rates.

MeSH terms

  • Complementarity Determining Regions / genetics*
  • Exome / genetics
  • Genome
  • Humans
  • Neoplasms / immunology
  • Neoplasms / mortality*
  • Neoplasms / virology*
  • Receptors, Antigen, T-Cell / genetics*
  • Receptors, Antigen, T-Cell / immunology
  • Survival Rate
  • V(D)J Recombination
  • Viruses / pathogenicity

Substances

  • Complementarity Determining Regions
  • Receptors, Antigen, T-Cell